Quaternized Tertiary Amine Drug Linker for Targeted Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ligand-drug conjugates (LDCs) face challenges in using tertiary amine-containing drugs, as they often require modification to attach to a linker moiety, leading to reduced biological activity or undesired changes, and it is unpredictable which site of conjugation will provide the most efficient release of the active drug.
Innovation Solution
The development of LDC compositions with a specific structure that utilizes the tertiary amine nitrogen as the site of conjugation, incorporating cleavable units capable of selective cleavage by proteases, glutathione, or lysosomal conditions, ensuring the release of fully active tertiary amine-containing drugs at the target site while minimizing exposure to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a tertiary amine-containing drug is modified to provide a site for attachment to a linker moiety, then the drug can be incorporated into an LDC, but the biological activity is significantly reduced or pharmacological properties change undesirably
Solution Approach 1:
The invention extracts the tertiary amine nitrogen from the drug molecule and uses it as the conjugation site, rather than modifying the drug structure. The quaternization step adds a methyl group to the nitrogen, creating a stable conjugation point while preserving the rest of the drug molecule intact, thus maintaining biological activity.
Solution Approach 2:
Instead of modifying the drug to create a conjugation site (conventional approach), the invention inverts the approach by quaternizing the nitrogen of the intact drug molecule and using that quaternized nitrogen as the attachment point to the linker, thereby avoiding structural modification of the pharmacologically active portion of the molecule.
2Ease of manufacture
If an alternative site of conjugation is introduced into a tertiary amine-containing drug, then the drug can be incorporated into an LDC, but unpredictable release efficiency occurs
Solution Approach 1:
The invention introduces a specific linker structure as an intermediary between the quaternized nitrogen and the drug molecule. This linker contains a cleavable functional group (such as a hydrazone or ester bond) that mediates the controlled release of the drug at the target site, providing predictable and efficient release mechanisms.
3Reliability
If the tertiary amine nitrogen is used as the site of conjugation, then fully active drug can be released at the target site, but the drug structure must be quaternized which adds complexity
Solution Approach 1:
The invention changes the chemical parameter of the nitrogen atom by quaternization, converting it from a tertiary amine to a quaternary ammonium ion. This parameter change creates a permanent positive charge and a stable conjugation site that maintains drug activity while enabling reliable attachment to the linker moiety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for targeted and efficient release of active drugs at abnormal cell sites, reducing side effects and maintaining maximum biological activity, with specific cleavage mechanisms enhancing drug delivery specificity.
Implementation Method 1
Ww of Q1 is capable of selective cleavage by a regulatory or intracellular protease in comparison to serum proteases
Implementation Method 2
W′-E of Q2 provides a glycosidic bond cleavable by a glycosidase located intracellularly
Implementation Method 3
capable of selective cleavage by glutathione through disulfide exchange
Implementation Method 4
more reactive to hydrolysis under lower pH conditions present in lysosomes in comparison to physiological pH of serum
Data Source
AI summary
Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action.Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.